Press

Irwin Naturals Acquiring Ketamine Media

Sep 30 • 3 min read

Irwin Naturals Inc. (CSE: IWIN | OTC: IWINF | FRA: 97X) today announced a definitive agreement to purchase all of the issued and outstanding shares of Keta Media, LLC dba Ketamine Media, the nation’s leading growth platform for clinics offering ketamine-assisted therapy. With a global network dedicated to improving patient outcomes, KM has established relationships with clinics…

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

Sep 30 • 3 min read

PharmaTher Holdings Ltd.( OTCQB: PHRRF | CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, today released business highlights and audited financial results for its fiscal year ended May 31, 2022. All amounts in this press release are…

Psyence Group Completes Export of Psilocybin Mushrooms to Portugal

Sep 29 • 4 min read

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) is pleased to announce that it has successfully exported medical grade psilocybin mushrooms to Psilo Pharma Inc. (“Psilo Pharma”), from its federally licensed ISO22000 certified production facility in Southern Africa, through its research partner in Portugal (the “Research Partner”). In February 2022, Psyence received an import permit…

Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application

Sep 29 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3Q | OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce that the company has produced 1.5 mg psilocybin microdose capsules. These capsules were produced according to defined manufacturing processes and product specifications as…

Biomind and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System

Sep 29 • 3 min read

Biomind Labs Inc. (NEO: BMND | OTC: BMNDF | FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules, is pleased to announce the receipt of a Controlled Substances License and the commencement…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435